Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

1.

Color blind.

Petsko GA.

Genome Biol. 2004;5(12):119. Epub 2004 Nov 26. No abstract available.

PMID:
15575974
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Colour-coded cures.

Kingsland J.

New Sci. 2005 Jun 11-17;186(2503):42-7. No abstract available.

PMID:
16178100
[PubMed - indexed for MEDLINE]
3.

Not black and white: BiDil may work best for African Americans--but do we know why?

[No authors listed]

New Sci. 2005 Jun 11-17;186(2503):3. No abstract available.

PMID:
16178098
[PubMed - indexed for MEDLINE]
4.

The paradox of race in the Bidil debate.

Crawley L.

J Natl Med Assoc. 2007 Jul;99(7):821-2. No abstract available.

PMID:
17668653
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

What's right (and wrong) with racially stratified research and therapies.

Sade RM.

J Natl Med Assoc. 2007 Jun;99(6):693-6. No abstract available.

PMID:
17595943
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Bidil: recontextualizing the race debate.

S├ęguin B, Hardy B, Singer PA, Daar AS.

Pharmacogenomics J. 2008 Jun;8(3):169-73. doi: 10.1038/sj.tpj.6500489. Epub 2008 Jan 15. No abstract available.

PMID:
18195727
[PubMed - indexed for MEDLINE]
7.

"Special treatment": BiDil, Tuskegee, and the logic of race.

Reverby SM.

J Law Med Ethics. 2008 Fall;36(3):478-84. doi: 10.1111/j.1748-720X.2008.294.x.

PMID:
18840239
[PubMed - indexed for MEDLINE]
8.

Race as a proxy for drug response: the dangers and challenges of ethnic drugs.

Bowser R.

De Paul Law Rev. 2004 Spring;53(3):1111-26. No abstract available.

PMID:
16211761
[PubMed - indexed for MEDLINE]
9.

"Ethnic drugs".

Kahn J.

Hastings Cent Rep. 2005 Jan-Feb;35(1):1 p following 48. No abstract available.

PMID:
15799501
[PubMed - indexed for MEDLINE]
10.

U.S. to review drug intended for one race.

Saul S.

N Y Times Web. 2005 Jun 13:A1, A15. No abstract available.

PMID:
15966118
[PubMed - indexed for MEDLINE]
11.

Food & Drug Administration panel approves heart failure medication aimed at African-Americans.

[No authors listed]

Pharmacogenomics. 2005 Jul;6(5):455. No abstract available.

PMID:
16705760
[PubMed - indexed for MEDLINE]
12.

BiDil's impact.

Puckrein G, Yancy CW.

Nat Biotechnol. 2005 Nov;23(11):1343; discussion 1343-4. No abstract available.

PMID:
16273052
[PubMed - indexed for MEDLINE]
13.

Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.

Colvin-Adams M, Taylor AL.

Cleve Clin J Med. 2007 Mar;74(3):227-34. Review.

PMID:
17375804
[PubMed - indexed for MEDLINE]
Free Article
14.

The isosorbide-hydralazine story: is there a case for race-based cardiovascular medicine?

Ferdinand KC.

J Clin Hypertens (Greenwich). 2006 Mar;8(3):156-8. No abstract available.

PMID:
16522991
[PubMed - indexed for MEDLINE]
15.

Illuminating BiDil.

[No authors listed]

Nat Biotechnol. 2005 Aug;23(8):903. No abstract available.

PMID:
16082345
[PubMed - indexed for MEDLINE]
16.

Misreading race and genomics after BiDil.

Kahn J.

Nat Genet. 2005 Jul;37(7):655-6. No abstract available.

PMID:
15990879
[PubMed - indexed for MEDLINE]
17.

A cure for a race? Heart drug findings set off ethics debate.

Payne JW.

Washington Post. 2004 Nov 16:F1, F4. No abstract available.

PMID:
15700369
[PubMed - indexed for MEDLINE]
18.

Gray area for new heart failure drug. Although the FDA approved BiDil for blacks with heart failure, it may work in anyone.

[No authors listed]

Harv Heart Lett. 2005 Nov;16(3):1-2. No abstract available.

PMID:
16363036
[PubMed - indexed for MEDLINE]
19.

Color blind, or just plain blind?

Czap A.

Altern Med Rev. 2005 Jun;10(2):81-2. No abstract available.

PMID:
16032786
[PubMed - indexed for MEDLINE]
Free Article
20.

BiDil: false promises: faulty statistics and reasoning have lead to the first "racial medicine".

Kahn J.

Genewatch. 2005 Nov-Dec;18(6):6-9, 18. No abstract available.

PMID:
16459407
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk